<DOC>
	<DOCNO>NCT00087724</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy five fix dosage level FK962 placebo 24 week subject mild moderate Alzheimer 's disease . Patient visit every six week limit efficacy measurement week 6 18 .</brief_summary>
	<brief_title>A Randomized Study Evaluate FK962 Subjects With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Subject satisfies criteria clinical diagnosis probable AD Subject score = &lt; 4 Modified Hachinski Ischemia Scale screen visit Subject history evidence significant neurologic disease AD Subject history stroke Subject treat schizophrenia recurrent mood disorder within previous three year Subject hematologic solid malignancy diagnose within five year prior study entry Subject medically unstable COPD asthma Subject end stage CHF ( NYHA Class III IV ) unstable angina Subject evidence significant renal insufficiency Subject insulindependent diabetes mellitus HbA1C &gt; 8.5 % screening</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>